Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) have been given a consensus recommendation of "Hold" by the ten brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.67.

A number of equities research analysts recently issued reports on the stock. The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the company a "neutral" rating in a research note on Tuesday, August 2nd. Bank of America raised shares of Teva Pharmaceutical Industries from a "neutral" rating to a "buy" rating and lifted their price target for the company from $10.00 to $13.00 in a research note on Friday, August 5th. UBS Group assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, June 13th. They issued a "neutral" rating and a $10.00 price target on the stock. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday, June 17th.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $8.81 on Friday. The company has a debt-to-equity ratio of 2.07, a current ratio of 1.11 and a quick ratio of 0.74. The firm has a market cap of $9.78 billion, a price-to-earnings ratio of -9.27, a price-to-earnings-growth ratio of 3.42 and a beta of 1.27. The company has a 50 day moving average price of $9.12 and a 200-day moving average price of $8.72. Teva Pharmaceutical Industries has a 1-year low of $6.78 and a 1-year high of $11.34.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 58,163 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $9.04, for a total transaction of $525,793.52. Following the sale, the vice president now owns 2,974 shares of the company's stock, valued at approximately $26,884.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP David Matthew Stark sold 58,163 shares of the business's stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $9.04, for a total transaction of $525,793.52. Following the transaction, the vice president now owns 2,974 shares of the company's stock, valued at approximately $26,884.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Eliyahu Sharon Kalif sold 55,500 shares of the business's stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $10.07, for a total transaction of $558,885.00. Following the transaction, the chief financial officer now directly owns 9,376 shares in the company, valued at approximately $94,416.32. The disclosure for this sale can be found here. 0.82% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Cigna Investments Inc. New boosted its position in shares of Teva Pharmaceutical Industries by 5.0% during the 2nd quarter. Cigna Investments Inc. New now owns 21,575 shares of the company's stock valued at $163,000 after acquiring an additional 1,024 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in Teva Pharmaceutical Industries by 3.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 37,645 shares of the company's stock valued at $292,000 after buying an additional 1,307 shares during the period. National Bank of Canada FI raised its holdings in Teva Pharmaceutical Industries by 1.3% in the 1st quarter. National Bank of Canada FI now owns 109,526 shares of the company's stock valued at $1,025,000 after buying an additional 1,392 shares during the period. Morningstar Investment Services LLC raised its holdings in Teva Pharmaceutical Industries by 5.5% in the 1st quarter. Morningstar Investment Services LLC now owns 26,631 shares of the company's stock valued at $245,000 after buying an additional 1,395 shares during the period. Finally, Ensign Peak Advisors Inc raised its holdings in Teva Pharmaceutical Industries by 3.4% in the 4th quarter. Ensign Peak Advisors Inc now owns 45,850 shares of the company's stock valued at $367,000 after buying an additional 1,500 shares during the period. Institutional investors and hedge funds own 46.22% of the company's stock.

About Teva Pharmaceutical Industries

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Further Reading

• Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
• Tax Credits are the Incentives in the Inflation Reduction Act
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• 3 Banks Worth Considering For Q4
• MarketBeat: Week in Review 9/12 – 9/16
• Is There a Cure for What is Ailing Teladoc Stock?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.